We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a move that will result in an overhaul of the company’s corporate structure, Guidant President and CEO Ronald Dollens announced last week that he is retiring from the company at the end of the year.
While it’s still too early to tell what regulatory course Daniel Shultz will take in his tenure as acting chief of the FDA’s Center for Devices and Radiological Health (CDRH), he told D&DL last week that he doesn’t plan to stray far from the path that his predecessor, David Feigal, blazed.